Additionally, refinement and validation of methods to assess HRD genomic scarring in non-OV/BC types is needed to gain a comprehensive understanding of the role of BRCA1 and RAD51C methylation in tumourigenesis and drug resistance. This evidence concerns the gene BRCA1 and breast cancer.